Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

NCT05618041 is registered in ClinicalTrials.gov with Hebei Senlang Biotechnology Inc., Ltd. as lead sponsor.

NCT NCT05618041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05618041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Lead sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Phase
Not applicable
Overall status
Recruiting
Start date
September 7, 2022
Completion date
December 6, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, lymphoma, multiple myeloma